ReviewBiomedicines2025

Investigation into the Use of Surufatinib and Donafenib as Novel Multi-Kinase Inhibitors Therapeutic Agents in Managing Advanced Differentiated Thyroid Cancer: A Systematic Review.

Danut Dejeu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.